TEST CHANGE

Prazepam (Assayed as Nordiazepam)

0090672, PRAZE

Specimen Requirements:	
Patient Preparation:	Timing of specimen collection: Predose~~Pre-dose~~ (trough) draw at~~-~~ ~~At~~ steady state concentration.
Collect:	Gray (potassium oxalate/sodium fluoride).~~Potassium Oxalate/Sodium Fluoride).~~ Also acceptable: Plain red, green (sodium heparin), lavender~~Red, Green (Sodium Heparin), Lavender~~ (K2 or K3EDTA) or pink (K2EDTA).
Specimen Preparation:	Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP standard transport tube.~~Standard Transport Tube.~~ (Min: 1 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Gel separator tubes. Plasma or whole blood collected in light blue (sodium citrate). Hemolyzed specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years (Avoid repeated freeze/thaw cycles)
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed:	Tue, Fri
Reported:	1-7~~5~~ days
Note:	
CPT Codes:	80346 (Alt code: G0480)
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

Prazepam is not detected in serum due to its rapid metabolism to nordiazepam. Adverse effects may include dizziness, fatigue, drowsiness, ataxia, and weakness. ~~and weakness.~~

~~This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.~~

Reference Interval:

Effective November 16, 2015

Dose-Related Range:	Prazepam (Dose: 20-60 mg/d) (Assayed as Nordiazepam)	
Nordiazepam:	100-1500 ng/mL	
Toxic:	Greater than 2500 ng/mL	